GET DAILY SIGNALSDiebold Nixdorf (DBD): $85 Analyst Target Points to +41% Upside
Key Takeaways
- The central DBD price target of $85 is the arithmetic mean of two verified analyst targets reviewed: DA Davidson at $80 and Wedbush at $90.
- The target sits roughly 41% above the latest verified share price of $60.09, making the required move very large.
- The analyst range is narrow at $80–$90, but coverage is thin at roughly two to three firms, so the "consensus" reflects only a handful of views.
- The strongest supporting factors are a third-quarter earnings beat, a new share-repurchase authorization, and steady demand across banking and retail automation.
- The biggest risks are management's reduced full-year 2026 guidance, margin and raw-material cost pressures, and a recent slide to a new 52-week low.
- Readers can explore additional pages covering Diebold Nixdorf's Major News, Today's Price Move, Forecast, and Earnings for deeper context on each.
- For a broader view of AI-driven trading tools, explore Trending AI Robots.
Analyst Price Targets and Consensus View
Diebold Nixdorf, Incorporated (NYSE: DBD) builds ATMs, cash recyclers, self-checkout systems, point-of-sale hardware, and the Vynamic software suite for banks and retailers. Analyst coverage of the post-restructuring company remains thin. Two named targets were reviewed: DA Davidson maintains a Buy rating with an $80 target (October 30, 2026), and Wedbush maintains an Outperform rating with a $90 target (October 27, 2026). Both firms had earlier carried $100 targets but trimmed them following the third-quarter report. The mean of those two figures is $85, and independent aggregators such as S&P Global and Yahoo Finance report a comparable $85 average target across a similar $80–$90 range.
In my view, sentiment is uniformly bullish but concentrated. Both covering firms view the shares as undervalued relative to earnings power, yet both reduced their expectations after guidance was lowered. That narrow, two-to-three-analyst base means the $85 figure should be read as a directional benchmark rather than a broad, diversified consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
As of the latest verified close, Diebold Nixdorf traded near $60.09 with a market capitalization of roughly $2.0 billion. Reaching $85 would require an advance of about 41%, which is a very large move over any reasonable horizon. The company reported third-quarter adjusted earnings of about $1.34 per share, ahead of the roughly $1.31 consensus estimate, with revenue near $994 million that also exceeded expectations. However, management simultaneously narrowed and reduced its full-year 2026 outlook — citing unfavorable revenue mix and raw-material cost pressures — which triggered a post-earnings pullback and a new 52-week low near $53.81 in late October.
A path toward $85 would likely require both a recovery in the shares toward their former $92 high and renewed confidence that margins can stabilize while revenue grows modestly. The stock currently trades near 28 times trailing earnings, so a meaningful portion of any upside would need to come from earnings growth and margin execution rather than multiple expansion alone.
What Could Support a Move Toward the Target
- Earnings momentum: Third-quarter results beat on both EPS and revenue, a sign of resilient underlying demand.
- Capital returns: A newly authorized share-repurchase program signals management confidence and can support per-share earnings.
- Turnaround positioning: Since emerging from its 2023 Chapter 11 restructuring, the company has rebuilt its balance sheet and improved free cash flow.
- Recurring revenue mix: Growth in software and managed services carries higher margins than hardware, supporting long-term profitability.
- Analyst framing: Both covering firms retain Buy or Outperform ratings, implying they see the post-guidance decline as overdone.
What Could Prevent the Target From Being Reached
- Guidance reduction: Lowered full-year revenue, adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization), and free-cash-flow targets weigh on sentiment.
- Margin pressure: Unfavorable product mix and raw-material costs directly challenge the profitability narrative.
- Technical weakness: The stock recently printed a new 52-week low and remains well below its $92.08 prior high.
- Thin coverage: With only a couple of analysts, the target is fragile and vulnerable to any single downgrade or further cut.
- Rating pressure: Independent rating services such as Weiss Ratings and Wall Street Zen have downgraded the shares to Hold, reflecting reduced conviction.
Technical Levels and Market Structure
The shares trade within a wide 52-week range of roughly $52.87 to $92.08. The late-October low near $53.81 marks the clearest near-term support zone, while the $60 area now serves as a psychological level as the stock attempts to stabilize. On the upside, the prior $92.08 high and the $80–$90 analyst target band represent the principal resistance zones. A sustained recovery above the $65–$70 area would be an early sign of improved structure, but the stock remains in a longer-term downtrend from its earlier peak. From what I see, monitoring these levels closely helps put the analyst target in perspective.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a research horizon of roughly 12 months, though the exact window can vary by firm, and neither DA Davidson nor Wedbush publishes a fixed, guaranteed timeframe. Investors should watch the next quarterly earnings report for confirmation that margin pressures are easing and that full-year guidance is holding, along with any analyst revisions to the $80–$90 targets. The share-buyback execution, banking and retail capital-spending trends, raw-material costs, and broader technology-sector sentiment are all worth monitoring. Because coverage is so thin, any rating change is likely to move the stock disproportionately.
AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a low-coverage, volatile name like Diebold Nixdorf, such tools can help traders spot shifting trends, monitor existing positions, and discover new opportunities more efficiently than manual screening. I find this approach useful when evaluating names with limited analyst attention, as it adds a systematic layer to my own review process. Traders looking to complement their own research with systematic, data-driven signals can explore the platform's daily signal stream.
Final Assessment
The $85 central target is the average of two verified analyst targets — $80 from DA Davidson and $90 from Wedbush — and implies a very large, roughly 41% advance from the current price near $60.09. Support comes from a recent earnings beat, a buyback authorization, and a leaner post-restructuring business model, while the principal obstacles are reduced full-year guidance, margin pressures, and weak technical positioning after a fresh 52-week low. The narrow $80–$90 range reflects unusually thin coverage, meaning the target is more sensitive to individual revisions than a typical large-cap consensus. Whether the shares can reach $85 will depend on margin stabilization, sustained execution, and a recovery in investor confidence — factors that remain uncertain and should be monitored closely.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DBD in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 30, 2026
DBD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 25 of 27 cases where DBD's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where DBD's RSI Oscillator exited the oversold zone, 12 of 14 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 23 of 29 cases where DBD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
Following a +4.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where DBD advanced for three days, in 177 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DBD as a result. In 37 of 55 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.
The Moving Average Convergence Divergence Histogram (MACD) for DBD turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 32 similar instances when the indicator turned negative. In 22 of the 32 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
DBD moved below its 50-day moving average on October 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DBD crossed bearishly below the 50-day moving average on October 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 70%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DBD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
The Aroon Indicator for DBD entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.041) is normal, around the industry mean (-1.906). P/E Ratio (19.042) is within average values for comparable stocks, (9.554). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.824). Dividend Yield (0.000) settles around the average of (0.069) among similar stocks. P/S Ratio (0.606) is also within normal values, averaging (70.383).
The Tickeron SMR rating for this company is 67 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. DBD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DBD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PackagedSoftware
Advertisement